Abstract
The efficacy of cephalexin monohydrate 50 mg/kg/d was evaluated in a placebo-controlled, double-blind, crossover study of patients with cystic fibrosis. Over a 2 year period, 17 patients with mild-moderate disease were treated for 4 month intervals with either cephalexin or placebo. One patient developed drug-related vulvovaginitis and dropped-out of the study. Although colonization by cephalexin-resistant S. aureus was not observed, 2 patients had an increase in sputum concentration of Ps. aeruginosa during antibiotic therapy.
Patients previously colonized with ≥ 106 CFU/ml Ps. aeruginosa of H. influenzae had no alteration in flora. Six of 8 patients colonized with ≥ 106 CFU/ml S. aureus had a decrease in S. aureus concentration to < 104 CFU/ml during treatment with cephalexin. During periods of drug treatment, significantly reduced S. aureus colonization (7% versus 26% of cultures), increased weight gain (1.2 versus 0.2 kg/4 months) and less hospitalizations (2 versus 15) were observed (P < 0.01). There were no differences in pulmonary function tests, chest x-rays, or sputum production during periods of antibiotic or placebo treatment.
Cephalexin, when compared to placebo, altered the microbial flora and clinical course of some patients with cystic fibrosis.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loening-Baucke, V., Mischler, E. & Myers, M. 790 CEPHALEXIN IN CYSTIC FIBROSIS: A PLACEBO-CONTROLLED STUDY. Pediatr Res 12 (Suppl 4), 495 (1978). https://doi.org/10.1203/00006450-197804001-00795
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-00795